Table 1.

Baseline characteristics for oral vs. infusible in patients with relapsing forms of MS.

	Oral (n = 1509)		Infusible (n = 495)		p-Values
	n or mean	% or SD	n or mean	% or SD
Disease duration (years, SD)	10.1	6.5	10.7	6.9	0.215
Age (years, SD)	42.5	11.6	38.6	11.5	<0.001
Gender—Female	370	72.7%	378	76.4%	0.182
Previous DMT*					<0.001
Interferons	74	14.5%	84	17.0%
Glatiramer acetate	137	26.9%	150	30.3%
Natalizumab	145	28.5%	60	12.1%
Rituximab	6	1.2%	0	0.0%
Fingolimod	17	3.3%	23	4.7%
Dimethyl fumarate	1	0.2%	2	0.4%
None	121	23.8%	165	33.3%
Other	8	1.6%	11	2.1%
Contrast enhancement on baseline MRI	90	20.4%	143	34.1%	<0.001
Disease burden on baseline MRI					0.629
Mild	232	45.6%	208	42.0%
Moderate	141	27.7%	152	30.7%
Severe	53	10.4%	49	9.9%
Missing	83	16.3%	86	17.4%

DMT, disease modifying therapy; SD, standard deviation; n, sample size.

^*Within 6 months prior to starting study drug.